Skip to main content
Michael Poirier, MD, Pediatric Emergency Medicine, Norfolk, VA, Children's Hospital of The King's Daughters

MichaelPPoirierMD

Pediatric Emergency Medicine Norfolk, VA

Associate Professor, Pediatrics, Eastern Virginia Medical School

Are you Dr. Poirier?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 44 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Michael Poirier, MD is a pediatric emergency medicine physician in Norfolk, Virginia. He is currently licensed to practice medicine in Virginia, Ohio, and Georgia. He is affiliated with Children's Hospital of The King's Daughters and is an Associate Professor at Eastern Virginia Medical School.

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterResidency, Pediatrics, 1990 - 1993
  • University of Alabama School of Medicine
    University of Alabama School of MedicineClass of 1990

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 1996 - 2024
  • OH State Medical License
    OH State Medical License 1994 - 1996
  • GA State Medical License
    GA State Medical License 1993 - 1995
  • AL State Medical License
    AL State Medical License Active through 1993
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Emergency Medicine

Awards, Honors, & Recognition

  • Fellow (FACEP) American College of Emergency Physicians
  • Fellow (FAAP) American Academy of Pediatrics

Publications & Presentations

PubMed

Press Mentions

  • Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results
    Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial ResultsAugust 17th, 2021
  • Qualigen Calls It Quits on COVID Antiviral After Pouring Millions into R&D
    Qualigen Calls It Quits on COVID Antiviral After Pouring Millions into R&DAugust 17th, 2021
  • Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
    Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19July 14th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations